

TABLE 178: NAIVE SVR GENOTYPE 4 WITH PEARL-I STUDY ADDED: ODDS RATIOS, RELATIVE RISKS, AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODE

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR 48	0.96 (0.11 to 1.79)	-2.20 (-46.32 to 40.99)
SOF24 + RBV24		1.63 (1.18 to 1.84)	32.34 (9.37 to 43.15)
SOF12 PR12		1.86 (1.58 to 1.94)	44.36 (29.77 to 48.16)
PAR/RIT12 + OMB12 + RBV12		1.88 (1.69 to 1.95)	45.55 (35.58 to 48.40)
SOF24 + RBV24	SOF12 + RBV12	1.66 (0.91 to 13.95)	32.68 (-7.50 to 76.27)
SOF12 PR12		1.91 (1.01 to 17.52)	45.24 (0.73 to 90.29)
PAR/RIT12 + OMB12 + RBV12		1.95 (1.04 to 17.79)	46.92 (3.61 to 91.27)
SOF12 PR12	SOF24 + RBV24	1.14 (0.94 to 1.55)	11.40 (-5.49 to 33.95)
PAR/RIT12 + OMB12 + RBV12		1.15 (0.99 to 1.57)	12.63 (-0.92 to 35.05)
PAR/RIT12 + OMB12 + RBV12	SOF12 PR12	1.01 (0.91 to 1.18)	1.03 (-8.76 to 15.24)
Random effect model	Residual deviance	7.617 vs. 8 data points	
	Deviance information criteria	52.445	
Fixed effect model	Residual deviance	7.601 vs. 8 data points	
	Deviance information criteria	52.425	

Cri = credible interval; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RIT = ritonavir; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.